A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer

Summary

Participants of this study will have a diagnosis of a solid tumor cancer that has come back to its original location or spread beyond its original location (advanced), came back (relapsed) or worsened (refractory) after standard treatments, or no standard treatments are available for the participants' cancer. The purpose of this study if to find the highest dose of MQ710 that causes few or mild side effects in participants with a solid tumor cancer diagnosis.

Timeline

Start

2023-05-04

Primary completion

2028-05-04

Completion

2028-05-04

Drugs

Indications